Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Stanford University

Status: Enrolling

Conditions: Neoplasms; Carcinomas (Including Squamous Cell and Adenocarcinoma)

Treatments: Procedure: blood draw

Study type: Observational

Funder types: Other

Identifiers

NCT00349830

VAR0006 (Other Identifier)

77923 (Other Identifier)

IRB-13535 (Other Identifier)

5R01CA18829804 (Other Grant/Funding Number)

Details and patient eligibility

About

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Full description

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

1. Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
2. Prior diagnosis of cancer or suspected of having cancer
3. Karnofsky performance status of greater than 70
4. Standard pretreatment evaluation
5. Signed Stanford University Human Subjects Committee consent